HTD Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Lifyorli Commercial AdoptionRapid patient starts, broad prescriber adoption, and coverage across more than 70% of lives indicate a strong launch foundation. These access and utilization advantages can support durable oncology revenue growth as physicians gain experience and treatment adoption expands.
Strong Revenue Growth And Raised OutlookAccelerating revenue from both Korlym and Lifyorli shows that growth is becoming more diversified across endocrinology and oncology. The raised full-year outlook signals management sees sustained commercial momentum rather than relying on a single product or short-lived demand.
Conservative Balance SheetMinimal leverage and a substantial equity base give Corcept meaningful financial flexibility to fund clinical development, commercial expansion, and potential regulatory activities internally. This reduces balance-sheet strain and improves resilience if pipeline timing or operating conditions become less favorable.
Bears Say
Recent Profitability CompressionThe sharp decline in net margin indicates that strong gross product economics have not translated into equally durable bottom-line performance recently. If lower operating profitability persists, Corcept may have less earnings leverage from revenue growth and reduced capacity to convert commercial momentum into shareholder returns.
Cooling Cash-flow TrendCash generation remains substantial and closely tracks net income, but the recent decline shows weaker cash-flow growth than in prior years. Continued cooling could constrain internally funded investment in the pipeline and commercial infrastructure, even though current liquidity and cash conversion remain healthy.
Relacorilant Regulatory UncertaintyRelacorilant could materially broaden Corcept’s Cushing’s syndrome opportunity, but its prior complete response letter demonstrates that approval is not assured. Until the FDA decision, regulatory uncertainty can delay commercialization, increase execution demands, and limit confidence in the projected franchise expansion.
Corcept Therapeutics News
HTD FAQ
What was Corcept Therapeutics Inc.’s price range in the past 12 months?
Currently, no data Available
What is Corcept Therapeutics Inc.’s market cap?
Corcept Therapeutics Inc.’s market cap is CHF10.41B.
When is Corcept Therapeutics Inc.’s upcoming earnings report date?
Corcept Therapeutics Inc.’s upcoming earnings report date is Nov 04, 2026 which is in 37 days.
How were Corcept Therapeutics Inc.’s earnings last quarter?
Corcept Therapeutics Inc. released its earnings results on Jul 29, 2026. The company reported CHF0.297 earnings per share for the quarter, beating the consensus estimate of CHF0.02 by CHF0.277.
Is Corcept Therapeutics Inc. overvalued?
According to Wall Street analysts Corcept Therapeutics Inc.’s price is currently Undervalued.
Does Corcept Therapeutics Inc. pay dividends?
Corcept Therapeutics Inc. does not currently pay dividends.
What is Corcept Therapeutics Inc.’s EPS estimate?
Corcept Therapeutics Inc.’s EPS estimate is 0.67.
How many shares outstanding does Corcept Therapeutics Inc. have?
Corcept Therapeutics Inc. has 108,098,400 shares outstanding.
What happened to Corcept Therapeutics Inc.’s price movement after its last earnings report?
Corcept Therapeutics Inc. reported an EPS of CHF0.297 in its last earnings report, beating expectations of CHF0.02. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Corcept Therapeutics Inc.?
Currently, no hedge funds are holding shares in CH:HTD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corcept Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF115.80 (― Upside)
CHF115.80 (― Upside)
Blogger Sentiment
Bullish
CH:HTD Sentiment 70%
Sector Average 64%
Sector Average 64%
Insider Transactions
Sold Shares
Worth CHF3.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.33%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.85%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Corcept Therapeutics Inc.
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
HTD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights robust commercial momentum and meaningful clinical and regulatory progress: strong Q2 financials (+32% revenue growth), a fast and well‑covered Lifyorli launch with survival data supporting uptake, record Korlym prescribing driven by shifting clinical awareness, and multiple near‑term trial readouts. Offsetting these positives are residual regulatory risk for relacorilant (prior CRL, PDUFA Dec 17, 2026), tolerability concerns and mixed statistical significance in early ALS results, and the usual clinical/regulatory execution risks across the pipeline. On balance, the positive financial performance, rapid oncology launch, and pipeline catalysts outweigh the noted risks.View all CH:HTD earnings summariesHTD Stock 12 Month Forecast
Average Price Target
―SCYNEXIS
―
Kiniksa Pharmaceuticals
―
Liquidia Technologies
―
Citius Oncology
―
Nasus Pharma Ltd.
―